Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Delcroix, R. Channick, N. Galiè, H. A. Ghofrani, P. Jansa, F. O. Le Brun, S. Mehta, L. Perchenet, T. Pulido, B. K. S. Sastry, O. Sitbon, R. Souza, A. Torbicki, G. Simonneau, L. Rubin (Leuven, Belgium; Boston, San Diego, United States Of America; Bologna, Italy; Giessen, Germany; Prague, Czech Republic; Allschwil, Switzerland; London, Canada; Mexico City, Mexico; Hyderabad, India; Le Kremlin Bicêtre, France; São Paulo, Brazil; ECZ-Otwock, Poland). Is 6-minute walk distance (6MWD) associated with long-term outcomes in pulmonary arterial hypertension (PAH)? Results from SERAPHIN. Eur Respir J 2013; 42: Suppl. 57, 3417

Member's Comments

No comment yet.

Related content which might interest you: Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension Source: Eur Respir J 2012; 40: 1410-1419 Year: 2012 Effects of sildenafil on 6-minute walk distance (6MWD) and WHO functional class (FC) in pulmonary arterial hypertension (PAH) patients after 1 year of treatment Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Relationship between sit-to-stand test and six-minute walk test in patients with pulmonary arterial hypertension Source: International Congress 2015 – The challenge of choosing the best physical and functional assessment methods Year: 2015 Comparability of shuttle walk test with 6-minutes walk test in pulmonary diseases with emphasis on pulmonary arterial hypertension Source: Annual Congress 2013 –Mechanisms contributing to exercise limitation in health and respiratory, cardiac and pulmonary vascular diseases Year: 2013 The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension Source: Eur Respir Rev 2013; 22: 487-494 Year: 2013 Prognostic impact of oxygen saturation during the 6-minute walk test in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Prognostic significance of 6-minute walk test in non-group 1 pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Patient perspectives on exercise training in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension Source: Eur Respir J 2010; 36: 1294-1301 Year: 2010 Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension Source: Eur Respir J 2006; 27: 114-120 Year: 2006 Clinical predictors of pulmonary hypertension in sarcoidosis Source: Eur Respir J 2008; 32: 296-302 Year: 2008 Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 6MWD in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 464s Year: 2003 Role of exercise cardiac index to predict NYHA functional class, 6-minute walk test distance and survival in idiopathic, heritable and anorexigen-associated pulmonary arterial hypertension Source: Annual Congress 2011 - Physiology of human pulmonary hypertension Year: 2011 The six-minute walking test accompanied by pulse oximetry and ventilation assessment in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Pressure-flow relationship during exercise predicts transplant-free survival in patients with pre-capillary pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: new pathophysiological insights Year: 2015 An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Physiological response to the six-minute walk test in pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 667-672 Year: 2005 Safety related to maximal cardiopulmonary exercise testing in patients with pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016